Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old

Frontiers in Immunology

Érika D. Candido²  Fabyano B. Leal²  Guilherme P. Scagion²  Danielle B. L. Oliveira⁵  Daniela S. Rosa⁶  Edecio Cunha-Neto⁶  Jorge Kalil⁶  Silvia B. Boscardin⁶  Keity S. Santos⁶  Verônica Coelho⁶  Marcelo A. Ferreira⁷  João Paulo S. Nunes⁸  Rafael R. Almeida⁸  Greyce Luri Sasahara⁸  Jhosiene Y. Magawa⁸  Andreia C. Kuramoto⁸  Roberto Carlos V. Silva⁸  Giuliana X. Medeiros⁸  Fernanda R. Bruno⁸  Edison L. Durigon⁹ 

[1] Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, Brazil;Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil;Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil;Faculdade de Medicina da Universidade de São Paulo, Departamento de Clínica Médica, Disciplina de Alergia e Imunologia Clínica, São Paulo, Brazil;Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil;Instituto de Investigação em Imunologia (iii), Instituto Nacional de Ciências e Tecnologia (INCT), São Paulo, Brazil;Laboratório de Biologia Celular, LIM59, Departamento de Patologia da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil;Laboratório de Imunologia, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil;Laboratório de Virologia, Plataforma Científica Pasteur da Universidade de São Paulo, São Paulo, Brazil;

关键词: COVID-19;    vaccine;    CoronaVac;    T cell responses;    antibody;    neutralizing antibody;   

DOI  :  10.3389/fimmu.2022.812126

来源: DOAJ

【 摘 要 】

CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection.

【 授权许可】

Unknown